

Applicants : David J. Pinsky et al.  
U.S. Serial No.: CPA of 09/374,586  
Filed : August 13, 1999  
Page 2

546C1

2. (Amended) The method of claim 1, wherein the active polypeptide fragment of CD39 polypeptide is administered and is a mutated or a truncated form of the CD39 polypeptide.

9. (Amended) The method of claim 1, wherein the administration of the CD39 polypeptide or the active polypeptide fragment thereof is effected prior to stroke onset in the human subject.

10. (Amended) The method of claim 1, wherein the administration of the CD39 polypeptide or the active polypeptide fragment thereof is effected at the onset of stroke in the human subject.

11. (Amended) The method of claim 1, wherein the administration of the CD39 polypeptide or the active polypeptide fragment thereof is effected after stroke onset in the human subject.


546C4

17. (Amended) A method for determining whether a compound inhibits platelet aggregation or leukocyte accumulation by increasing ADP catabolism and does not increase incidence of intracerebral hemorrhage, so as to treat or prevent thrombotic or ischemic disorder in a subject, comprising:

- (a) administering the compound to an animal, which is a model for the thrombotic or

Applicants : David J. Pinsky et al.  
U.S. Serial No.: CPA of 09/374,586  
Filed : August 13, 1999  
Page 3

ischemic disorder, before, concurrently  
with or after step (b);

- 
- (b) inducing the thrombotic or ischemic disorder in the animal;
  - (c) measuring the stroke outcome and the incidence of intracerebral hemorrhage in the animal;
  - (d) measuring platelet and/or fibrin deposition in ischemic tissue in the animal; and
  - (e) comparing the stroke outcome and the platelet and/or fibrin deposition in the presence of the compound with in the absence of the compound so as to determine whether the compound is capable of treating or preventing the thrombotic or ischemic disorder in the subject.--

#### REMARKS

Claims 1-13 and 16-26 are currently pending in the above-identified application. By this Preliminary Amendment applicant has hereinabove amended claims 1, 2, 9, 10, 11 and 17. Support for amended claim 1 can be found in the specification as originally filed at, inter alia, page 6, lines 2-8. Support for amended claim 2 can be found in the specification as originally filed at, inter alia, page 6, lines 10-12. Support for amended claim 9 can be found